Negara: Indonesia
Bahasa: Bahasa Indonesia
Sumber: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/MARYLAND/15/2016, BX-69A (VICTORIA LINEAGE)), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE VIRUS (A/MICHIGAN/45/2015, NYMC X-275), A/SWITZERLAND/8060/2017 (H3N2)-LIK
AVENTIS PHARMA - Indonesia
B/PHUKET/3073/2013-LIKE VIRUS (B/PHUKET/3073/2013, WILD TYPE), B/COLORADO/06/2017-LIKE VIRUS (B/MARYLAND/15/2016, BX-69A (VICTORIA LINEAGE)), A/MICHIGAN/45/2015 (H1N1)PDM09-LIKE VIRUS (A/MICHIGAN/45/2015, NYMC X-275), A/SWITZERLAND/8060/2017 (H3N2)-LIK
15 Mcg /15 MCG /15 MCG /15 MCG
SUSPENSI INJEKSI
DUS, 1 PREFILLED SYRINGE @ 0.5 ML
SANOFI PASTEUR - France
2020-07-08
VAXIGRIPTETRA® SH QUADRIVALENT INFLUENZA VACCINE (SPLIT VIRION, INACTIVATED) SUSPENSION FOR INJECTION IN PRE-FILLED SYRINGE QUALITATIVE AND QUANTITATIVE COMPOSITION Influenza virus (inactivated, split) of the following strains*: A/Sydney/5/2021 (H1N1)pdm09-like virus (A/Sydney/5/2021, SAN-013) ..................................... 15 micrograms HA** A/Darwin/9/2021 (H3N2)-like virus (A/Darwin/9/2021, IVR-228) ...................................... 15 micrograms HA** B/Austria/1359417/2021-like virus (B/Michigan/01/2021, wild type) .................................................................................... 15 micrograms HA** B/Phuket/3073/2013 - like virus (B/Phuket/3073/2013, wild type) .................................................................................... 15 micrograms HA** For one 0.5 mL dose * propagated in fertilised hens’ eggs from healthy chicken flocks ** haemagglutinin This vaccine complies with the WHO recommendations (Southern Hemisphere) for the 2023 season. For the full list of excipients, see section List of excipients VaxigripTetra SH may contain traces of eggs, such as ovalbumin, and of neomycin, formaldehyde and octoxinol-9, which are used during the manufacturing process (see section Contraindications). PHARMACEUTICAL FORM Suspension for injection in pre-filled syringe. The vaccine, after shaking gently, is a colourless opalescent liquid. CLINICAL PARTICULARS THERAPEUTIC INDICATIONS VaxigripTetra SH is indicated for the prevention of influenza disease caused by the two influenza A virus subtypes and the two influenza B virus types contained in the vaccine for: - active immunisation of adults, including pregnant women, and children from 6 months of age. - passive protection of infant(s) from birth to less than 6 months of age following vaccination of pregnant women (see Sections posology and method of administration; Special warnings and precautions for use; Fertility, pregnancy and lactation and Pharmacodynamic properties – clinical trials). The use of VaxigripTetra SH Baca dokumen lengkapnya